Abstract: The present application discloses an establishing method for establishing a dyeing model, a dyeing method, a device, and a storage medium which are applied to the dyeing technology field. The establishing method includes: obtaining historical data of dyeing a workpiece, the historical data includes historical dyeing time of the workpiece and historical color value of the workpiece after dyeing; and obtaining the dyeing model by training an initial model based on the historical data. The dyeing model is established using the historical data, and can establish a relationship between the dyeing time and the color value of the workpiece after dyeing. Based on the dyeing model, the dyeing time required for the workpiece can be determined according to a color value of the workpiece after dyeing. A precise dyeing process can be realized by determining the dyeing time using the dyeing model instead of determining the dyeing time manually.

Abstract: This invention relates to compounds of general Formula I and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract: This invention relates to compounds of general Formula I and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R1a, R2, R3, R4, and (R5)a are as defined herein, to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable salts thereof, and to methods of using such compounds, pharmaceutically acceptable salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract: An array substrate, a manufacturing method thereof, and a display device including the array substrate. The array substrate includes a plurality of gate line groups and a plurality of data lines disposed on a substrate, the plurality of gate line groups intersecting with the plurality of data lines to define a plurality of pixel units arranged in an array, wherein each of the plurality of gate line groups includes a first gate line and a second gate line insulated from each other, and orthographic projections of the first gate line and the second gate line of each of the plurality of gate line groups on the substrate at least partially overlap.

Abstract: An array substrate and a method of manufacturing the same are provided. The method of manufacturing an array substrate includes: forming a black matrix and an organic insulating pattern on a base substrate with a thin film transistor formed thereon, wherein the black matrix and the organic material pattern are formed by using an identical mask.

Abstract: An array substrate and a method of manufacturing the same are provided. The method of manufacturing an array substrate includes: forming a black matrix and an organic insulating pattern on a base substrate with a thin film transistor formed thereon, wherein the black matrix and the organic material pattern are formed by using an identical mask.

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R1a, R2, R3, R4, and (R5)a are as defined herein, to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable salts thereof, and to methods of using such compounds, pharmaceutically acceptable salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract: The disclosure discloses a display substrate and a manufacturing method thereof, and a display device, the display substrate comprises a display region and a periphery region, a first electrode line is arranged at the periphery region, an insulating layer is arranged on the first electrode line, a first through hole is provided in the insulating layer at a position corresponding to the first electrode line, a contact electrode is provided in the first through hole, a second electrode line is arranged on the insulating layer, the second electrode line is electrically connected to the first electrode line through the contact electrode. In the disclosure, the contact electrode is provided between the first and second electrode lines, thus when the second electrode line is etched, the first electrode line is protected by the contact electrode from being damaged by etchant, thus saving production cost and improving production efficiency.

Abstract: An array substrate, a manufacturing method thereof, and a display device including the array substrate. The array substrate includes a plurality of gate line groups and a plurality of data lines disposed on a substrate, the plurality of gate line groups intersecting with the plurality of data lines to define a plurality of pixel units arranged in an array, wherein each of the plurality of gate line groups includes a first gate line and a second gate line insulated from each other, and orthographic projections of the first gate line and the second gate line of each of the plurality of gate line groups on the substrate at least partially overlap.

Abstract: The disclosure discloses a display substrate and a manufacturing method thereof, and a display device, the display substrate comprises a display region and a periphery region, a first electrode line is arranged at the periphery region, an insulating layer is arranged on the first electrode line, a first through hole is provided in the insulating layer at a position corresponding to the first electrode line, a contact electrode is provided in the first through hole, a second electrode line is arranged on the insulating layer, the second electrode line is electrically connected to the first electrode line through the contact electrode. In the disclosure, the contact electrode is provided between the first and second electrode lines, thus when the second electrode line is etched, the first electrode line is protected by the contact electrode from being damaged by etchant, thus saving production cost and improving production efficiency.

Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is (4-12)-membered heterocyclyl; Ring B is a fused benzene ring selected from the group consisting of: Ring A, ring B, ring C, R1, R1a, R2, R3, R4, L2, n, t, w, and z are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of glucokinase, the method comprising administering to a mammal an effective amount of a compound of formula (I).

Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is (4-12)-membered heterocyclyl; Ring B is a fused benzene ring selected from the group consisting of: Ring A, ring B, ring C, R1, R1a, R2, R3, R4, L2, n, t, w, and z are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of glucokinase, the method comprising administering to a mammal an effective amount of a compound of formula (I).

Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is (4-12)-membered heterocyclyl; Ring B is a fused benzene ring selected from the group consisting of: Ring A, ring B, ring C, R1, R1a, R2, R3, R4, L2, n, t, w, and z are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of glucokinase, the method comprising administering to a mammal an effective amount of a compound of formula (I).

Abstract: Triptolide derivatives of Formula (I), their pharmaceutically acceptable salts and optical isomers, Formula (I): wherein, C5 and C6 are connect with each other by a C-C single bond or double bond; when C5 and C6 are connected with C-C single bond, X and Y represent independently hydrogen, oxygen, hydroxyl, halogen, lower alkyl-oxy, lower alkyl-amino, mercapto, lower alkyl-thio, the group of formula —OCOR, —OSO2OR or —OPO(OH)2, each of which is attached to C5 and C6, R represents —(CH2)nCO2Na, —(CO2)nCO2K, or —(CH2)nCH3, wherein n=1-6; Z represents hydrogen, oxygen, hydroxyl, halogen, lower alkyl-oxy, lower alkyl-amino, mercapto, lower alkyl-thio, the group of formula -OCOR, -OSO2OR or —OPO(OH)2, each of which is linked at C14-position, R represents —(CH2)nCO2Na, —(CO2)nCO2K, or —(CH2)nCH2, wherein n=1-6; wherein, the“______” linked with X, Y, and Z represents the stereochemistry orientations “” or “” , but X and Y cannot both be hydrogen atom at the same time, methods for preparing the triptolides and the

Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is (4-12)-membered heterocyclyl; Ring B is a fused benzene ring selected from the group consisting of: Ring A, ring B, ring C, R1, R1a, R2, R3, R4, L2, n, t, w, and z are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of glucokinase, the method comprising administering to a mammal an effective amount of a compound of formula (I).

Abstract: The invention relates to triptolide derivatives of Formula (I), their pharmaceutically acceptable salts and optical isomers, Formula (I): wherein, C5 and C6 connect with each other by a C—C single bond or double bond; when C5 and C6 are connected with C—C single bond, X and Y represents independently hydrogen, oxygen, hydroxyl, halogen, lower alkyl-oxy, lower alkyl-amino, mercapto, lower alkyl-thio, the group of formula —OCOR, —OSO2R or —OPO(OH)2, each of which is attached to C5 and C6, R represents —(CH2)nCO2Na, —(CO2)nCO2K, or —(CH2)nCH3, wherein n=1-6; Z represents hydrogen, oxygen, hydroxyl, halogen, lower alkyl-oxy, lower alkyl-amino, mercapto, lower alkyl-thio, the group of formula —OCOR, —OSO2R or —OPO(OH)2, each of which is linked at C14-position, R represents —(CH2)nCO2Na, —(CO2)nCO2K, or —(CH2)nCH2, wherein n=1-6; wherein, the “_” linked with X, Y, and Z represents “” or “”, but X and Y cannot both be hydrogen atom at the same time, the methods for preparing them and their use as antiphlogistic

Abstract: Compounds of formula I are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus

Abstract: The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.

Abstract: The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.